Novo Nordisk Lifts Outlook as Wegovy Pill Drives Stronger Sales Growth
The Big Market Report Take
Novo Nordisk A/S said this year’s declines won’t be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg’s Sanne Wass reports from Copenhagen.
Go deeper: Get Morningstar's independent analyst rating, fair value estimate, and portfolio tools for this story.
Morningstar Research →Affiliate link — we may earn a commission at no cost to you.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- U.K. Bond Market Anxiety: Why Friday Could Bring a New Yield SpikeMarketWatch44m ago
- Rimini Street Battles Revenue Headwinds With Enticing AI StrategySeeking Alpha59m ago
- Euro-Zone Wage Growth Accelerating — ECB Weighs Rate Hike ImpactBloomberg Markets1h ago
Alphabet's AI Shift: Google Parent Challenges Nvidia's Data Center DominanceThe Motley Fool1h ago